Dialysis Tubing Set Correction: Vantive Updates Use Instructions for Prismaflex and Oxiris Sets

The FDA has since determined that this device may cause temporary or reversible health problems, or—though unlikely—serious health problems. The affected products and recommendations for what to do with the devices below have not changed. This recall involves updating instructions for affected devices, and does not involve removing them from where they are used or sold.

Affected Product

The FDA is aware that Vantive has issued a letter informing affected customers that Prismaflex Control Units have updated use instructions.

Affected devices:

Device Name	Product Code	UDI-DI	Lot Numbers
PRISMAFLEX ST100 SET US	107636US	00085412954073	All lots including and manufactured after 24G0072
PRISMAFLEX ST150 SET US	107640US	00085412917696	All lots including and manufactured after 24F0085
OXIRIS SET	112016	07332414102234	All lots including and manufactured after 24G0041Z
PRIMSAFLEX M100 SET	106697	07332414064556	All lots including and manufactured after 24F0077CA
PRISMAFLEX M150 SET	109990	07332414090005	All lots including and manufactured after 24F0100CA
PRISMAFLEX HF1000 SET	107140	07332414069254	All lots including and manufactured after 24G0034CA
PRISMAFLEX HF1400 SET	107142	07332414069315	All lots including and manufactured after 24F0094CA
PRISMAFLEX TPE2000 SET	114093	07332414111038	All lots including and manufactured after 24J0106

What to Do

When using affected products, monitor the deaeration chamber during therapy to ensure it remains in an upright position within the holder.

On January 6, Vantive sent all affected customers a letter recommending the following actions:

You may continue to perform therapy using affected Prismaflex sets. Please monitor the deaeration chamber during therapy to ensure it remains in an upright position within the holder.
Vantive is aware of customers who have experienced this issue and attempted to further secure the deaeration chamber in an upright position. If attempting to secure the deaeration chamber in an upright position, please consider the following:
- Ensure there are no kinks in the tubing and that the deaeration chamber remains visible.
- If the Prismaflex Control Unit issues an “Air in Blood” alarm, check if air is present. If there is no air present, check if the deaeration chamber is dislodged from the holder and ensure there are no clots present.
  - If no dislodgement, please follow the operator’s manual instructions for “Air in Blood” alarm.
  - In case of dislodgement with clotting, follow the associated instructions within the Prismaflex Control Unit operator’s manual to stop the therapy and replace the set.
  - Only in case of dislodgement without clotting or any other alarms, if the chamber is secured in an upright position, follow the associated instructions within the Prismaflex Control Unit operator’s manual to proceed with treatment.
If you purchased this product from a distributor, please note that responding using the Vantive Customer Reply Form is not applicable. If a response is requested by your distributor or wholesaler, please respond to the supplier according to their instructions.
If you distributed this product to other facilities or departments within your institution, please forward a copy of this communication to them.

Reason for Correction

Vantive stated that Prismaflex Set deaeration chambers may dislodge from the Prismaflex Control Unit, as shown above. This issue does not affect PrisMax Control Units, as these devices have a different deaeration chamber holder design.

A dislodged deaeration chamber may lead to an “Air in Blood” alarm on the Prismaflex Control Unit. The alarm may occur during the priming phase prior to initiating therapy, or during therapy. This may result in delays or interruptions to therapy and blood loss due to clotting and failure to return blood manually.

As of December 17, Vantive has not reported any serious injuries or deaths associated with this issue.

Device Use

Different Prismaflex sets are used with PrismaFlex control units or PrisMax control units in providing continuous fluid management and renal replacement therapies, blood purification, or therapeutic plasma exchange.

Additional FDA Resources

Contact Information

Customers in the U.S. with adverse reactions, quality problems, or questions about this recall should contact Vantive at 833-542-2778.

Unique Device Identifier (UDI)

The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly.

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

Timeline of Communication Updates

Date	Actions
03/16/2026	The FDA updated this communication to inform the public that this issue has been classified as a Class II Recall.
01/14/2026	The FDA issued an Early Alert communication to notify the public of a potentially high-risk device issue.